cdmo.directory
← Compare landing

Cell Therapies vs Hillgene

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/celltherapies/hillgene

CategoryCell TherapiesHillgene
Listed sitecdmocdmo
SummaryGMP contract manufacturer of autologous and allogeneic cell therapies from first-in-human trials through commercial supply, with two decades of experience in CAR-T, mesenchymal stromal cells, TILs, and pluripotent stem cell derivatives. Offers end-to-end cold chain management, process development, quality control analytics, and regulatory consulting across Australia and Asia-Pacific.Hillgene is a leading CDMO provider specializing in cell therapy manufacturing, offering end-to-end solutions for CAR-T, TCR-T, CAR-NK, and UCAR-T cell therapies with GMP facilities in Suzhou and Belgium.
Services
  • Cell Therapy Manufacturing
  • Autologous Cell Therapy Manufacturing
  • Allogeneic Cell Therapy Manufacturing
  • Technology Transfer
  • Process Development
  • CMC Analytical Development
  • Quality Control Testing
  • Cold-Chain Storage & Logistics
  • CMC Regulatory Submission Support
  • Cell Therapy Manufacturing
  • Autologous Cell Therapy Manufacturing
  • Allogeneic Cell Therapy Manufacturing
  • Lentiviral Vector Manufacturing
  • mRNA Manufacturing
  • Quality Control Testing
  • Regulatory Affairs
  • CMC Regulatory Submission Support
Modalities
  • Cell Therapy
  • Gene Therapy
  • Cell Therapy
  • mRNA
  • Gene Therapy
Indications
  • Oncology
  • Oncology
  • Immunology
Locations
  • Headquarters / Manufacturing & Development, Melbourne, Victoria, Australia
  • Headquarters, Suzhou, Jiangsu, China
  • R&D Center, Suzhou, Jiangsu, China
  • GMP Facility, Belgium, Belgium
Certifications
  • TGA · Identifier: TGA-licensed
  • FDA · Identifier: FDA inspection-ready
  • PMDA · Identifier: PMDA inspection-ready
  • EMA · Identifier: EMA inspection-ready
  • FDA · Identifier: DMF filing approval for genetically modified K562 feeder cells
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.